<DOC>
	<DOCNO>NCT01466894</DOCNO>
	<brief_summary>This multi-center , randomize , placebo-controlled , double-blind , dose-selection , multiple dose administration study comprise three group , 40 patient active treatment placebo group . Patients biopsy proven nonalcoholic steatohepatitis ( NASH ) elevate liver enzymes randomize undergo liver MRI scan receive Imm 124-E placebo 24 week . During period , patient follow clinical laboratory effect . At end 24 week treatment , patient undergo second liver MRI scan . Patients follow additional 4 week safety completion treatment .</brief_summary>
	<brief_title>Safety Efficacy Study IMM 124-E ( Bovine Colostrum ) Patients With Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Men woman age 18 75 year ( inclusive ) Subjects biopsy proven NASH ( NAS â‰¥ 4 ) within one year prior screen Elevated liver enzyme screen least within past 6 month ( ALT &gt; 30 woman , ALT &gt; 40 men ) Normal slightly impair synthetic liver function ( serum albumin &gt; 3.5gm % , INR 0.81.5 ) BMI 18 40 ( inclusive ) Subjects able adhere visit schedule protocol requirement available complete study Women child bear potential must use adequate contraception Cow milk allergy lactose intolerance Excessive alcohol use ( Women &gt; 20 grams/day , Men &gt; 40 grams/day ) . Current treatment Insulin Incretins Decompensated liver disease Other concomitant cause liver disease ( viral hepatitis , autoimmune liver disease , metabolic liver disease , vascular liver disease ) Subjects know HIV positive Subjects undergone surgery within last 3 month Subjects prior gastrointestinal surgery Subjects history Inflammatory Bowel Disease Subjects receive elemental diet parenteral nutrition Subjects infectious , immunemediated active malignant disease ( last 3 month ) Subjects know clinically significant systemic disease Subjects treat antiNASH therapy ( ) thiazolidinediones , vitamin E , SAMe , betaine , milk thistle , gemfibrozil , antiTNF therapy probiotic ) within 3 month liver biopsy Subjects treat type immune modulatory drug , include systemic steroid NSAIDs , within last 3 month Subjects receive either Immuron , 6MP , Methotrexate , Cyclosporine , antiTNF alpha therapy ( Infliximab , Adalimumab , Etanercept ) antiintegrin therapy ( namixilab ) within past 12 month Known history drug alcohol abuse , include positive urinary drug abuse screen screen visit Subjects pregnant confirm screen test Any acute medical situation ( e.g . acute infection ) within 48 hour study start consider significance Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Nonalcoholic fatty liver disease</keyword>
	<keyword>NAFLD</keyword>
	<keyword>Fatty liver</keyword>
	<keyword>NASH</keyword>
</DOC>